How does decompensated heart failure influence antiarrhythmic choices?

• A. It does not affect antiarrhythmic dosing or choices.
• B. It limits certain drugs, and favors amiodarone due to safer hemodynamics.
• C. It necessitates use of class IC agents as first-line.
• D. It requires immediate catheter ablation in all patients.

Answer: (B)

When the heart is decompensated, maintaining safe hemodynamics becomes the priority in selecting antiarrhythmics. Drugs that worsen contractility or provoke proarrhythmia in a failing heart are avoided. Class IC agents (flecainide, propafenone) have strong sodium-channel blockade and slow conduction that can be dangerous in structural heart disease or acute heart failure, so their use is limited in this setting. Amiodarone stands out because it exerts antiarrhythmic effects with relatively little negative inotropy and good tolerability in unstable or failing hearts, making it the preferred choice for rhythm control when hemodynamics are compromised. Other options may be used with caution but carry higher risks of hemodynamic compromise or QT-related complications, so they are not as favored as amiodarone in decompensated heart failure. Immediate catheter ablation is not required for all patients and is considered only based on specific circumstances, not as a universal approach.